Assembly Bioscie Stock Price, News & Analysis

Assembly Biosciences, Inc. (Nasdaq: ASMB) announced a grant of stock options for 16,000 shares to a new employee at an exercise price of $1.87 per share. The options will vest over four years and were given as a material inducement for employment. This grant aligns with the company’s 2017 Inducement Award Plan and adheres to Nasdaq Listing Rule 5635(c)(4). Assembly Bio specializes in innovative therapeutics for hepatitis B virus (HBV), aiming to provide curative treatments for the 296 million people affected globally.

Assembly Biosciences (ASMB) reported its financial results for Q1 2022, highlighting a cash position of $146.5 million, down from $174.6 million at year-end 2021, expected to fund operations into Q4 2023. The company introduced a new small molecule entry inhibitor targeting HBV and HDV, expanding its pipeline. Research and development expenses decreased to $17.2 million from $18.6 million year-over-year, while general and administrative costs also fell to $6.0 million. Net loss narrowed to $23.1 million ($0.48 per share) from $27.2 million ($0.69 per share) in Q1 2021.

Assembly Biosciences (ASMB), a clinical-stage biotech company, announced the granting of stock options to a new employee for 19,000 shares at an exercise price of $2.06, the closing price on April 1, 2022. The stock options will vest over four years, with the first quarter vesting after one year. This grant is part of Assembly Bio's 2017 Inducement Award Plan and was approved by the independent Compensation Committee. Assembly Bio focuses on developing therapies for hepatitis B virus and aims to provide curative treatments for the 296 million affected individuals worldwide.

Assembly Biosciences announces the addition of Professor Michael P. Manns, MD, to its leadership team, focusing on hepatitis B and delta viruses. A webcast is scheduled for March 31, 2022, to unveil a new research program targeting HBV and HDV via an innovative orally bioavailable small-molecule approach. Key speakers include Manns, Assembly Bio CEO John McHutchison, and Chief Scientific Officer William Delaney. The company aims to advance therapies for the 296 million individuals with HBV globally, emphasizing the urgent need for treatment options.

Assembly Biosciences (ASMB) reported its Q4 and full-year 2021 financial results, highlighting a net loss of $129.9 million, up from $62.2 million in 2020. The cash position decreased to $174.6 million as of December 31, 2021. Revenues dropped significantly to $6.3 million, compared to $79.1 million in 2020, primarily due to prior collaborations. R&D expenses decreased to $68.5 million, while general and administrative expenses fell to $28.8 million. The company aims to advance its pipeline with key studies expected in 2022, including the initiation of trials for new core inhibitor candidates.

Assembly Biosciences, Inc. (Nasdaq: ASMB) announced that CEO John McHutchison will speak at the SVB Leerink 11th Annual Global Healthcare Conference on February 17, 2022, at 3:40 p.m. ET. The virtual fireside chat will be accessible via webcast on Assembly Bio's website, with a replay available for 30 days. Assembly Bio focuses on innovative therapies for hepatitis B virus (HBV) and aims to develop curative treatments for the 270 million people affected worldwide. Its portfolio includes next-generation core inhibitors targeting HBV replication.

Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company, announced the grant of stock options to two new employees, allowing the purchase of 7,000 shares at an exercise price of $2.45 each. The options have a ten-year term and vest over four years. This action aims to attract talent through financial incentives and follows Nasdaq Listing Rule requirements. Assembly Bio focuses on developing therapies targeting hepatitis B virus, aiming to provide innovative treatments for the 270 million infected globally.

Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company focused on hepatitis B virus (HBV) therapies, announced that CEO John McHutchison will present at the HC Wainwright Virtual BIOCONNECT Conference from January 10-13, 2022. The presentation will be available for on-demand viewing starting January 10, 2022, at 7:00 a.m. EST on the company's website. Assembly Bio aims to develop curative therapies for the 270 million people worldwide living with HBV, leveraging its innovative oral core inhibitors and combination studies.

Assembly Biosciences, a clinical-stage biotechnology company listed on Nasdaq under the symbol ASMB, has outlined its development pipeline for 2022, focusing on hepatitis B virus (HBV) treatments. Key milestones include sharing preliminary data from three Phase 2 studies of vebicorvir (VBR) and advancing ABI-H3733 and ABI-4334 clinical trials. The company aims to explore new antiviral mechanisms while managing risks related to clinical study timelines and financial resource allocation. The CEO expressed optimism about the company's strategy and research potential.